Richman Douglas D, Margolis David M, Delaney Martin, Greene Warner C, Hazuda Daria, Pomerantz Roger J
San Diego VA Healthcare System and University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0679, USA.
Science. 2009 Mar 6;323(5919):1304-7. doi: 10.1126/science.1165706.
Although combination therapy for HIV infection represents a triumph for modern medicine, chronic suppressive therapy is required to contain persistent infection in reservoirs such as latently infected CD4+ lymphocytes and cells of the macrophage-monocyte lineage. Despite its success, chronic suppressive therapy is limited by its cost, the requirement of lifelong adherence, and the unknown effects of long-term treatment. This review discusses our current understanding of suppressive antiretroviral therapy, the latent viral reservoir, and the needs for and challenges of attacking this reservoir to achieve a cure.
尽管针对HIV感染的联合疗法是现代医学的一项成就,但仍需要长期抑制性疗法来控制潜伏感染的CD4+淋巴细胞和巨噬细胞-单核细胞谱系细胞等储存库中的持续性感染。尽管取得了成功,但长期抑制性疗法受到成本、终身坚持治疗的要求以及长期治疗未知影响的限制。本综述讨论了我们目前对抑制性抗逆转录病毒疗法、潜伏病毒储存库的理解,以及攻克该储存库以实现治愈的需求和挑战。